{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:09:36Z","timestamp":1789675776889,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007613","name":"Ankara University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007613","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>We aimed to report real-world outcomes of transarterial radioembolization (TARE) in patients with intrahepatic cholangiocarcinoma (ICC), focusing on different microsphere types and posttreatment dosimetric approaches in relation to dose\u2013response and survival analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This multicenter retrospective single-arm cohort study included adult patients with intrahepatic cholangiocarcinoma treated with Y-90 glass or resin microspheres using lobar or segmental approaches between January 2014 and December 2024 across 13 centers. All posttreatment Y-90 Bremsstrahlung single photon emission tomography (SPECT)\/ computed tomography (CT) or Y-90 positron emission tomography (PET) images were reviewed. Post-treatment dose estimations were performed centrally by a nuclear medicine physician with 10\u00a0years of experience in dosimetric calculations using the VoxelDosimetry tool of Hermia software (Hermes Medical Solutions, Sweden). Mean perfused liver absorbed dose (PLAD), mean tumor absorbed dose (TAD), and mean whole-liver absorbed dose (WLAD) were calculated. Dosimetric analysis for Y-90 SPECT\/CT and PET\/CT were performed separately. Tumor response was assessed by comparing imaging obtained within 6\u00a0weeks before treatment and 2\u20134\u00a0months after treatment. Response categories were grouped as objective response (complete response\u2009+\u2009partial response) and nonresponse (stable disease\u2009+\u2009progressive disease) for treated lesions. Hepatotoxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) using serum Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and bilirubin levels within 3\u00a0months after TARE. Additionally, albumin\u2013bilirubin (ALBI) scores were calculated before and after treatment, and changes in ALBI grade were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Initially, data from 194 (110 female, 84 male; mean age 53.8\u2009\u00b1\u200916.6\u00a0years) patients were included. After excluding patients without survival status data, 180 patients were included in the overall survival (OS) analysis. Seventeen patients were excluded from dose\u2013response evaluation due to suboptimal posttreatment Y-90 imaging for dosimetric calculations. Survival analyses were performed on a per-patient basis, whereas dosimetric and response analyses were performed on a per-treatment-session basis. For dose response analysis, a total of 194 TARE sessions in 163 (101 female, 62 male; mean age 51.4\u2009\u00b1\u200912.6\u00a0years) patients were analyzed. Median (min\u2013max) of administered activities were 2.7 (1.4\u20136.1) GBq for glass microspheres and 1.4 (0.6\u20131.8) GBq for resin microspheres (p\u2009=\u20090.004). In separate analyses of SPECT and PET studies, higher TAD and PLAD values were observed in sessions analyzed with PET-based dosimetry (for mean TAD; 249.2\u2009\u00b1\u200926.6\u00a0Gy vs 114.8\u2009\u00b1\u200915.7\u00a0Gy, p\u2009&lt;\u20090.001, for mean PLAD; 102.1\u2009\u00b1\u200910.4\u00a0Gy vs 59.4\u2009\u00b1\u200911.3\u00a0Gy, p\u2009=\u20090.031). A significant positive trend between TAD and response category was observed in the resin microsphere sessions using Y-90 PET\u2013based dosimetry (Area Under Curve 0.693, p\u2009=\u20090.028). In the OS analysis of 180 patients (median follow-up 13.3\u00a0months, range 7\u201381), 128 deaths occurred. Medians of OS did not differ between patients treated with glass versus resin microspheres [17.4 (13.2\u201321.5, 95%CI) vs 16.6 (7.7\u201325.5, 95%CI) months, p\u2009=\u20090.80]. Among 107 patients included in time to progression (TTP) analysis, no significant difference in medians of TTP was observed between patients treated with glass and resin microspheres [12.1 (7.8\u201312.4, 95%CI) vs 14.5 (5.6- 14.4, 95%CI) months, p\u2009=\u20090.11]. One patient developed grade 2 hepatotoxicity and irreversible hepatic failure 10\u00a0months after a second TARE session due to tumor progression. In addition, cholangitis occurred in 1 patient and gastritis in 3 patients following TARE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This multicenter analysis suggests that TARE may provide encouraging survival outcomes with acceptable toxicity in patients with ICC, including salvage settings. A potential dose\u2013response association was identified in the resin microsphere subgroup evaluated with Y-90 PET-based dosimetry. Given the retrospective multicenter design and heterogeneity of imaging modalities, these findings should be considered hypothesis-generating and require confirmation in prospective studies using standardized posttreatment dosimetry.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08007-w","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:47:22Z","timestamp":1782182842000},"page":"6559-6568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dose\u2013Response and survival analysis after transarterial radioembolization for intrahepatic cholangiocarcinoma: A multicenter multicompartment dosimetry study"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6199-8551","authenticated-orcid":false,"given":"Cigdem","family":"Soydal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunc","family":"Ones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat Fani","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine Goknur","family":"Is\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalan Alan","family":"Selcuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naz\u0131m","family":"Coskun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan","family":"Kutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu Esen","family":"Akkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Onner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Gultekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semra","family":"Ince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u0131nar","family":"Ozbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyhan","family":"Karacavus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irem","family":"Mesci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efe","family":"Soydemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilge Volkan","family":"Salanc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcney","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman Melih","family":"Topcuo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fcge","family":"Otlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enes Mustafa","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaaddin","family":"Nayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hulya","family":"Peker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin Tugsan","family":"Ball\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Bilgili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre Can","family":"Celebioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erbil","family":"Arik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonca","family":"Eldem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"M.D","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Poyanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00fcrkay","family":"Toklu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Dilek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6khan","family":"Yuce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadime","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuriye Ozlem","family":"Kucuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"8007_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261\u201380.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8007_CR2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","volume":"76","author":"L Izquierdo-Sanchez","year":"2022","unstructured":"Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Klu\u00a8mpen H-J, et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA registry. J Hepatol. 2022;76:1109\u201321.","journal-title":"J Hepatol"},{"issue":"S1","key":"8007_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(S1):19\u201331.","journal-title":"Liver Int"},{"key":"8007_CR4","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","volume":"77","author":"M Vithayathil","year":"2022","unstructured":"Vithayathil M, Khan SA. Current epidemiology of cholangiocarcinoma in Western countries. J Hepatol. 2022;77:1690\u20138.","journal-title":"J Hepatol"},{"key":"8007_CR5","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.21037\/tcr-23-1278","volume":"12","author":"J-Q Yang","year":"2023","unstructured":"Yang J-Q, Wang X-G, Wu B. Incidence trend and prognosis of intrahepatic cholangiocarcinoma: a study based on the SEER database. Transl Cancer Res. 2023;12:3007\u201315.","journal-title":"Transl Cancer Res"},{"key":"8007_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","volume":"79","author":"D Alvaro","year":"2023","unstructured":"Alvaro D, Gores GJ, Walicki J, Hassan C, Sapisochin G, Komuta M, et al. EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023;79:181\u2013208.","journal-title":"J Hepatol"},{"issue":"8","key":"8007_CR7","doi-asserted-by":"publisher","first-page":"2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S, Chen L-T, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):2200015.","journal-title":"NEJM Evid"},{"key":"8007_CR8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"D-Y Oh","year":"2024","unstructured":"Oh D-Y, He AR, Bouattour M, Okusaka T, Qin S, Chen L-T, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9:694\u2013704.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"8007_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/COC.0b013e3181f47583","volume":"35","author":"A Kennedy","year":"2012","unstructured":"Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Radioembolization for the treatment of liver tumors: general principles. Am J Clin Oncol. 2012;35:91\u20139.","journal-title":"Am J Clin Oncol"},{"key":"8007_CR10","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1007\/s00270-024-03768-z","volume":"47","author":"G Keane","year":"2024","unstructured":"Keane G, Lam M, Braat A, Bruijnen R, Kaufmann N, De Jong H, et al. Transarterial radioembolization (TARE) global practice patterns: an international survey by the Cardiovascular and Interventional Radiology Society of Europe (CIRSE). Cardiovasc Intervent Radiol. 2024;47:1224\u201336.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"8007_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, et al. Radioembolization plus chemotherapy for firstline treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6:51.","journal-title":"JAMA Oncol"},{"key":"8007_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40658-021-00394-3","volume":"8","author":"C Chiesa","year":"2021","unstructured":"Chiesa C, Sjogreen-Gleisner K, Walrand S, et al. EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres. EJNMMI Phys. 2021;8:77.","journal-title":"EJNMMI Phys"},{"key":"8007_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102258","volume":"99","author":"J Edeline","year":"2021","unstructured":"Edeline J, Lamarca A, McNamara MG, Jacobs T, Hubner RA, Palmer D, et al. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. Cancer Treat Rev. 2021;99:102258.","journal-title":"Cancer Treat Rev"},{"key":"8007_CR14","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jceh.2022.03.008","volume":"12","author":"P Kumar","year":"2022","unstructured":"Kumar P, Mhaskar R, Kim R, Anaya D, Frakes J, Hoffe S, et al. Unresectable intrahepatic cholangiocarcinoma treated with radiation segmentectomy\/lobectomy using yttrium 90-labeled glass microspheres. J Clin Exp Hepatol. 2022;12:1259\u201363.","journal-title":"J Clin Exp Hepatol"},{"key":"8007_CR15","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00270-022-03183-2","volume":"45","author":"AN Gupta","year":"2022","unstructured":"Gupta AN, Gordon AC, Gabr A, Kalyan A, Kircher SM, Mahalingam D, et al. Yttrium-90 radioembolization of unresectable intrahepatic cholangiocarcinoma: long-term follow-up for 136-patient cohort. Cardiovasc Intervent Radiol. 2022;45:1117\u201328.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"8007_CR16","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00270-020-02569-4","volume":"43","author":"I Bargellini","year":"2020","unstructured":"Bargellini I, Mosconi C, Pizzi G, Lorenzoni G, Vivaldi C, Cappelli A, et al. Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study. Cardiovasc Intervent Radiol. 2020;43:1305\u201314.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"8007_CR17","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jvir.2022.10.042","volume":"34","author":"S Buettner","year":"2023","unstructured":"Buettner S, Braat A, Margonis GA, Brown DB, Taylor KB, Robinson TJ, et al. Survival and Toxicities after Yttrium-90 Transarterial Radioembolization of Cholangiocarcinoma in the RESiN Registry. J Vasc Interv Radiol. 2023;34:694-701.e3.","journal-title":"J Vasc Interv Radiol"},{"key":"8007_CR18","unstructured":"https:\/\/www.clinicaltrials.gov\/study\/NCT02807181"},{"key":"8007_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055742","volume":"8","author":"M Elschot","year":"2013","unstructured":"Elschot M, Vermolen BJ, Lam MG, et al. Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. PLoS ONE. 2013;8:e55742.","journal-title":"PLoS ONE"},{"key":"8007_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4103\/1450-1147.157120","volume":"14","author":"HR Roshan","year":"2015","unstructured":"Roshan HR, Azarm A, Mahmoudian B, et al. Advances in SPECT for optimizing the liver tumors radioembolization using yttrium-90 microspheres. World J Nucl Med. 2015;14:75\u201380.","journal-title":"World J Nucl Med"},{"key":"8007_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026174","volume":"6","author":"M Elschot","year":"2011","unstructured":"Elschot M, Nijsen JF, Dam AJ, et al. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS ONE. 2011;6:e26174.","journal-title":"PLoS ONE"},{"issue":"3","key":"8007_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1053\/j.semnuclmed.2019.01.005","volume":"49","author":"BA Tafti","year":"2019","unstructured":"Tafti BA, Padia SA. Dosimetry of Y-90 microspheres utilizing Tc-99m SPECT and Y-90 PET. Semin Nucl Med. 2019;49(3):211\u20137. https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.01.005.","journal-title":"Semin Nucl Med"},{"key":"8007_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/2191-219X-3-56","volume":"3","author":"YH Kao","year":"2013","unstructured":"Kao YH, Steinberg JD, Tay YS, et al. Post-radioembolization yttrium-90 PET\/CT - part 1: diagnostic reporting. EJNMMI Res. 2013;3:56.","journal-title":"EJNMMI Res"},{"key":"8007_CR24","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1097\/RLU.0b013e31821c9a11","volume":"36","author":"YH Kao","year":"2011","unstructured":"Kao YH, Tan EH, Ng CE, et al. Yttrium-90 time-of-flight PET\/CT is superior to Bremsstrahlung SPECT\/CT for postradioembolization imaging of microsphere biodistribution. Clin Nucl Med. 2011;36:e186-7.","journal-title":"Clin Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08007-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08007-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:38Z","timestamp":1787986838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08007-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8007"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08007-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Cigdem Soydal is a proctor of Sirtex Medical Inc in Turkiye.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u013011-1039\u201325, approval date: 23.12.2025. Meeting.","order":2,"name":"Ethics","label":"Ethical committee approval number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Human Research Ethics Committee of Ankara University (approval number: i11-1039\u201325, date: 23.12.2025) and conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments. Written informed consent was obtained from all participants.","order":5,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":7,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}